A retrospective study on the safety of immunotherapy in pregnancy

Authors

  • W. A. SHAIKH

    Corresponding author
    1. Allergy Clinic, Bombay Hospital Institute of Medical Sciences, Bombay, India
      Dr W. A. Shaikh, Akash Apartments, 6th Floor, Flat No. 6, Sane Guruji Road, Bombay-400 011, India.
    Search for more papers by this author

Dr W. A. Shaikh, Akash Apartments, 6th Floor, Flat No. 6, Sane Guruji Road, Bombay-400 011, India.

Summary

Eighty-one Indian patients received immunotherapy for allergic diseases during 109 pregnancies. Their allergy clinic records were analysed retrospectively and this revealed an incidence similar to or less than the general population with regard to abortion, perinatal mortality, prematurity, toxaemia and congenital malformation. A control group of 60 contemporary Indian patients (82 pregnancies) who refused immunotherapy were also analysed retrospectively and this revealed a higher incidence of abortion, prematurity and toxaemia as compared with those treated with immunotherapy. It is concluded that immunotherapy for allergic diseases is safe in pregnancy. Immunotherapy is safe even when it is initiated for the first time in a pregnant patient, an aspect not reported in any study until now.

Ancillary